Literature DB >> 11043156

The neurochemistry of phenylketonuria.

R Surtees1, N Blau.   

Abstract

UNLABELLED: The mechanisms by which deficiency of hepatic phenylalanine hydroxylase causes central nervous system disease are reviewed. The neurological disease appears to be secondary to increased concentrations of phenylalanine and a decrease in the concentrations of other large neutral amino acids, especially methionine and tyrosine, within the central nervous system. This causes a deficiency of the neurotransmitter dopamine, reduced protein synthesis and demyelination. Similar mechanisms appear to be operating when blood phenylalanine concentrations are in the range expected for early continuously treated phenylketonuria.
CONCLUSION: The severe brain disease found in phenylketonuria is caused by a raised blood phenylalanine content which increases the brain free phenylalanine and decreases the concentration of other large neutral amino acids. Brain protein synthesis is decreased, myelin turnover is increased and there are abnormalities in amine neurotransmitter systems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043156     DOI: 10.1007/pl00014370

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  49 in total

Review 1.  Drug Adverse Reaction Target Database (DART) : proteins related to adverse drug reactions.

Authors:  Zhi Liang Ji; Lian Yi Han; Chun Wei Yap; Li Zhi Sun; Xin Chen; Yu Zong Chen
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

3.  Platelet serotonin concentrations in PKU patients under dietary control and tetrahydrobiopterin treatment.

Authors:  A Ormazabal; M A Vilaseca; B Pérez-Dueñas; N Lambruschini; L Gómez; J Campistol; R Artuch
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 4.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

5.  Neurobehavioral problems associated with phenylketonuria.

Authors:  Steven D Targum; William Lang
Journal:  Psychiatry (Edgmont)       Date:  2010-12

6.  Regular exercise prevents oxidative stress in the brain of hyperphenylalaninemic rats.

Authors:  Priscila Nicolao Mazzola; Melaine Terra; Andrea Pereira Rosa; Caroline Paula Mescka; Tarsila Barros Moraes; Bruna Piccoli; Carlos Eduardo Jacques; Giovana Dalazen; Marcelo Xavier Cortes; Juliana Coelho; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2011-09-27       Impact factor: 3.584

7.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

8.  Mutation analysis of PAH gene in patients with PKU in western Iran and its association with polymorphisms: identification of four novel mutations.

Authors:  Reza Alibakhshi; Keyvan Moradi; Zahra Mohebbi; Keyghobad Ghadiri
Journal:  Metab Brain Dis       Date:  2013-09-19       Impact factor: 3.584

9.  Experimental evidence that phenylalanine provokes oxidative stress in hippocampus and cerebral cortex of developing rats.

Authors:  Carolina G Fernandes; Guilhian Leipnitz; Bianca Seminotti; Alexandre U Amaral; Angela Zanatta; Carmen R Vargas; Carlos S Dutra Filho; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2009-09-23       Impact factor: 5.046

Review 10.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.